Table 2.

Overview of clinical trials last updated from January 2015 to December 2016 of sorafenib and sunitinib, according to https://clinicaltrials.gov, with focus on frequency of hypertension.

Drug(s)	Diagnosis	No. of Patients	Phase	Design	Frequency of Hypertension	Clinical Trials. Gov	Ref.
Velcade (bortezomib) and sorafenib	Metastatic renal cell carcinoma	17	II	Interventional, non-randomized	35.3%	NCT01100242	[21]
Sorafenib	Metastatic renal cell carcinoma	39	III	Interventional, non-randomized	18%	NCT00586105	[22]
Sorafenib + PEG-interferon α-2b	Kidney cancer	1	NP	Interventional, single group assignment	Not yet reported	NCT00589550	[35]
Bevacizumab, sorafenib tosylate, and temsirolimus	Metastatic kidney cancer	331	NP	Interventional, randomized	Hypertension: Bevacizumab + sorafenib (46.7%) and temsirolimus + sorafenib (37.4%)	NCT00378703	[23]
Sorafenib	Renal cell carcinoma	9	II	Interventional, single group assignment	77.8%	NCT00854620	[24]
Sorafenib	Renal cell carcinoma	83	II	Interventional, single group assignment	48%	NCT00618982	[25]
Sunitinib	Advanced non-clear cell carcinoma	57	II	Interventional, single group assignment	61.4%	NCT00465179	[27]
Sunitinib	Kidney cancer (locally or metastatic)	24	II	Interventional, single group assignment	8.7%	NCT00459875	[28]
Sunitinib	Kidney cancer (locally or metastatic)	26	NP	Interventional, single group assignment	25%	NCT00849186	[29]
Sunitinib	Metastatic kidney cancer and melanoma	8	II	Interventional, single group assignment	Not reported	NCT00462982	[36]
Sunitinib	Renal cell cancer	25	I	Interventional, single group assignment	Not reported	NCT00694096	[37]
Sunitinib	Metastatic renal cell carcinoma	61	NP	Retrospective observational cohort	3.9%	NCT01827254	[30]
Sunitinib	Advanced renal cell cancer	32	II	Interventional, randomised, controlled trial	15.6%	From Pubmed.gov	[31]
Sorafenib tosylate with or without recombinant interferon α-2b	Metastatic renal cell carcinoma	Sorafenib tosylate with recombinant interferon α-2b: 40 Sorafenib tosylate without recombinant interferon α-2b: 40	II	Interventional	Sorafenib tosylate with recombinant interferon α-2b: 25% Sorafenib tosylate without recombinant interferon α-2b: 40%	NCT00126594	[38]
Sunitinib	Metastatic non-clear cell renal cell carcinoma	51	II	Interventional	45.1%	NCT01108445	[39]
Sunitinib + everolimus	Renal cell carcinoma	Everolimus 1. line/sunitinib 2. line: 238 Sunitinib 1. line/everolimus 2. line: 231	II	Interventional	Everolimus 1. line/sunitinib 2. line: 25.6% Sunitinib 1. line/everolimus 2. line: 36.4%	NCT00903175	[40]
Sunitinib	Renal cell carcinoma	179	II	Interventional	53.11%	NCT01147822	[41]
Sunitinib	Renal cell carcinoma	553	III	Interventional	40.51%	NCT00720941	[42]
Sunitinib	Renal cell carcinoma	148	III	Interventional	24.32%	NCT01064310	[43]

NP: Not provided.